BR112022026248A2 - Conjugados de citocinas - Google Patents
Conjugados de citocinasInfo
- Publication number
- BR112022026248A2 BR112022026248A2 BR112022026248A BR112022026248A BR112022026248A2 BR 112022026248 A2 BR112022026248 A2 BR 112022026248A2 BR 112022026248 A BR112022026248 A BR 112022026248A BR 112022026248 A BR112022026248 A BR 112022026248A BR 112022026248 A2 BR112022026248 A2 BR 112022026248A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- cytokine conjugates
- conjugates
- cytokine
- xten
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title abstract 3
- 108090000695 Cytokines Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063044335P | 2020-06-25 | 2020-06-25 | |
| US202163197875P | 2021-06-07 | 2021-06-07 | |
| US202163197944P | 2021-06-07 | 2021-06-07 | |
| PCT/US2021/038909 WO2021262985A1 (en) | 2020-06-25 | 2021-06-24 | Cytokine conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022026248A2 true BR112022026248A2 (pt) | 2023-01-17 |
Family
ID=79281847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022026248A BR112022026248A2 (pt) | 2020-06-25 | 2021-06-24 | Conjugados de citocinas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230265146A1 (https=) |
| EP (1) | EP4171609A4 (https=) |
| JP (1) | JP2023531496A (https=) |
| KR (1) | KR20230042014A (https=) |
| CN (1) | CN116096730A (https=) |
| AU (1) | AU2021296605A1 (https=) |
| BR (1) | BR112022026248A2 (https=) |
| CA (1) | CA3180251A1 (https=) |
| CO (1) | CO2023000048A2 (https=) |
| IL (1) | IL298626A (https=) |
| MX (1) | MX2022016389A (https=) |
| PH (1) | PH12022553408A1 (https=) |
| WO (1) | WO2021262985A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250114489A1 (en) * | 2022-02-15 | 2025-04-10 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
| IL320318A (en) * | 2022-10-19 | 2025-06-01 | Kalivir Immunotherapeutics Inc | Nucleic acids encoding tgf-beta inhibitor and il-12 and uses thereof |
| WO2025122957A1 (en) | 2023-12-08 | 2025-06-12 | Amunix Pharmaceuticals, Inc. | Protease activatable cytokines and methods for making and using the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020077276A1 (en) * | 1999-04-27 | 2002-06-20 | Fredeking Terry M. | Compositions and methods for treating hemorrhagic virus infections and other disorders |
| ES2610356T3 (es) * | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
| US8557961B2 (en) * | 2010-04-02 | 2013-10-15 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
| JP6355563B2 (ja) * | 2012-02-27 | 2018-07-11 | アムニクス オペレーティング インコーポレイテッド | Xten共役組成物およびそれを製造する方法 |
| IL319047A (en) * | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| JP7285220B2 (ja) * | 2017-05-18 | 2023-06-01 | モデルナティエックス インコーポレイテッド | 連結したインターロイキン-12(il12)ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子 |
| AU2018393111B2 (en) * | 2017-12-21 | 2025-07-10 | Amunix Pharmaceuticals, Inc. | Release segments and binding compositions comprising same |
| PE20210313A1 (es) * | 2018-03-28 | 2021-02-12 | Bristol Myers Squibb Co | Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso |
| WO2019222296A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| EP3849592A4 (en) * | 2018-08-23 | 2022-08-24 | Exalt Therapeutics, LLC | MODIFIED IFNL3 POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING FRAGMENT AND THEIR USES |
-
2021
- 2021-06-24 WO PCT/US2021/038909 patent/WO2021262985A1/en not_active Ceased
- 2021-06-24 IL IL298626A patent/IL298626A/en unknown
- 2021-06-24 JP JP2022579000A patent/JP2023531496A/ja active Pending
- 2021-06-24 AU AU2021296605A patent/AU2021296605A1/en active Pending
- 2021-06-24 MX MX2022016389A patent/MX2022016389A/es unknown
- 2021-06-24 BR BR112022026248A patent/BR112022026248A2/pt unknown
- 2021-06-24 CA CA3180251A patent/CA3180251A1/en active Pending
- 2021-06-24 CN CN202180045253.9A patent/CN116096730A/zh active Pending
- 2021-06-24 EP EP21828085.7A patent/EP4171609A4/en active Pending
- 2021-06-24 KR KR1020237002104A patent/KR20230042014A/ko active Pending
- 2021-06-24 PH PH1/2022/553408A patent/PH12022553408A1/en unknown
-
2022
- 2022-12-02 US US18/073,935 patent/US20230265146A1/en active Pending
-
2023
- 2023-01-04 CO CONC2023/0000048A patent/CO2023000048A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021262985A1 (en) | 2021-12-30 |
| MX2022016389A (es) | 2023-04-11 |
| IL298626A (en) | 2023-01-01 |
| CA3180251A1 (en) | 2021-12-30 |
| EP4171609A4 (en) | 2024-07-31 |
| KR20230042014A (ko) | 2023-03-27 |
| CO2023000048A2 (es) | 2023-03-27 |
| PH12022553408A1 (en) | 2024-04-22 |
| AU2021296605A9 (en) | 2023-03-09 |
| US20230265146A1 (en) | 2023-08-24 |
| JP2023531496A (ja) | 2023-07-24 |
| AU2021296605A1 (en) | 2023-02-23 |
| CN116096730A (zh) | 2023-05-09 |
| EP4171609A1 (en) | 2023-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022026248A2 (pt) | Conjugados de citocinas | |
| EA201170993A1 (ru) | Удлиненные рекомбинантные полипептиды и содержащие их композиции | |
| WO2021198706A3 (en) | Coronavirus vaccines | |
| BRPI0412799A (pt) | imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura | |
| MX2022014411A (es) | Polipéptidos il-12 activables y métodos de uso de estos. | |
| PE20231439A1 (es) | Proteinas f de hmpv estabilizadas por prefusion | |
| EA201190326A1 (ru) | Полипептиды гормона роста и способы их получения и применения | |
| ATE348883T1 (de) | Zusammensetzungen und verfahren mit analogen von g-csf | |
| BRPI0411363A (pt) | seqüências de ácidos nucléicos codificando e composições compreendendo peptìdeo sinal ige e/ou il-15 e processos para uso das mesmas | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| BR0107703A (pt) | Flavivìrus recombinantes e processos para uso dos mesmos | |
| BR112022006842A2 (pt) | Construtos de igf2 variante | |
| ATE426024T1 (de) | C-c chemokin rezeptor 3: ckr-3 oder eos-l2 | |
| EA202190267A1 (ru) | Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака | |
| ZA202501953B (en) | Masking polypeptide, activatable novel prodrugs and methods of use thereof | |
| MX2023002047A (es) | Proteinas de interleucina 2 (il-2) glucosiladas y usos de las mismas. | |
| ES2561483T3 (es) | Antígenos mutantes de GAS57 y anticuerpos de GAS57 | |
| DE60039677D1 (de) | Akt-3 nukleinsäure, polypeptide und deren verwendung | |
| BR112017022076A2 (pt) | fusões de mesotelina-variante iii de receptor de fator de crescimento epidérmico e métodos de uso das mesmas | |
| ATE464320T1 (de) | Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk) | |
| EA202191735A1 (ru) | Варианты альфа-галактозидазы человека | |
| EA202092065A1 (ru) | ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA) | |
| ZA202310639B (en) | Interleukin 15 variants | |
| ES2058565T3 (es) | Retrovirus recombinante defectivo, su aplicacion en la integracion de secuencias que codifican proteinas determinadas en el genoma de cultivos celulares infectables por el retrovirus salvaje correspondiente y adns recombinantes para la produccion de dicho retrovirus recombinante. | |
| BR112022022615A2 (pt) | Proteína nova e usos terapêuticos e cosméticos da mesma |